Characterization of BRCA1 and BRCA2 mutations in a large United States sample
about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersMeta-analysis of BRCA1 and BRCA2 penetranceChemotherapy of ovarian cancer in elderly patientsRecent Enhancements to the Genetic Risk Prediction Model BRCAPROCancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screeningBias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation CarriersTilting at quixotic trait loci (QTL): an evolutionary perspective on genetic causationWhat are genes "for" or where are traits "from"? What is the question?Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1Understanding the needs of women considering risk-reducing salpingo-oophorectomy.Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer--a population-based data linkage study.Incorporating medical interventions into carrier probability estimation for genetic counseling.Proteomic approach to breast cancer.Case-control study of fetal microchimerism and breast cancer.Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.Selecting a BRCA risk assessment model for use in a familial cancer clinic.Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer PatientsThe occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk womenPoly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes.Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an updateEvidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.Breast cancer risk among male BRCA1 and BRCA2 mutation carriersEvaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarianHereditary breast and ovarian cancer: new genes, new treatments, new concepts.Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience.In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.The BRCA1 variant p.Ser36Tyr abrogates BRCA1 protein function and potentially confers a moderate risk of breast cancer.Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.Breast cancer risks and risk prediction models.Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situA pilot study of knowledge and interest of genetic counseling and testing for hereditary breast and ovarian cancer syndrome among Puerto Rican women.
P2860
Q21144874-CF7ABF56-E0D7-4048-9A74-A7AF66692F07Q24654786-B5D406B4-2BA6-4CE9-95F1-7D4E1E126582Q26771397-0A0F23DE-8858-4FAA-8A10-F9431376289AQ26995389-422B9EEA-8A98-4ED6-8435-542CCA25DE21Q27001043-C602BF73-1A56-489C-A479-DBB972E6AA60Q28085448-5DA1DEE3-8BD3-4C42-92C5-1A7141D3C6F8Q28385221-9DBD0343-F05A-4705-9015-C05BC6DA41E1Q28393055-B5AB09D4-0419-4272-84FF-5542C2475185Q28539000-F5BBC4E9-D483-48CA-AA87-E4D0BCD4C632Q30419497-A1909467-7C7A-479C-8E3A-ABA145AEE251Q30448232-64D40D88-E5DD-4541-AAAE-C29F3937BF48Q30677729-1DD2F4E9-04DA-48A7-92CC-67B71D23C343Q33279688-9888EC0C-F2C3-44A9-B401-614B4754E2C8Q33301436-39CB7687-4E98-40E0-AE06-11BD51A42295Q33322513-B6B8AFBD-FF77-400D-87C7-A5B95F975E9AQ33338978-69F2CF5D-CB21-442A-B2C7-E486A9CD879BQ33395135-3E295490-7F76-47BA-B143-E0C90BE47DDDQ33416772-7D0D6821-E863-432E-800C-CF354572B5C1Q33584055-B49BB10D-4F8C-4717-B41B-C08045536EACQ33792732-A5950079-15D8-464A-B289-81F4CF098498Q33848119-5C6BA1FD-5BAE-4986-B9A2-F51A1EAD49E2Q33851843-D65DA530-92CE-4E80-8A18-019B6541F645Q34154918-996B8929-578F-459D-9A9D-395DE704814EQ34471501-CD81D25E-873F-4B14-BE08-3BD6F4A1AF64Q34501206-F6BE2E28-3105-42D1-AA9F-45EDCE5798F9Q34548726-4038F941-C3B9-471C-B35B-97197087D659Q34613604-DAF45B60-4769-4FC3-8021-F562773DD55AQ34625221-B8F28A94-60C2-41A1-93F4-E3FDCD1F0A48Q34718829-45C69598-ED66-479A-B4D7-8094A6604EC8Q34806825-B85D65AA-DE86-44CE-B832-BE2D47B47120Q34945185-7C60B712-12AC-429B-B558-95E51D1F49D8Q35019634-BA4475CC-DCD3-4ADE-80F6-CB061B381CAEQ35022825-F6C34842-7F17-4F5B-8C65-945213FA4A10Q35052323-A0BA0BB2-7049-4BE1-8293-BFBD08C05060Q35105959-8060A9E4-E320-41CB-A4EA-E5D69E5D8DA1Q35138569-F1132AFD-CBB8-40D8-9E88-695F189A5928Q35263848-32C90215-E8D6-426D-B9A8-F565D2D6B637Q35399596-8070CCE0-38C4-4D8A-BA6D-389400B6321FQ35531714-D3DEBB0D-36EF-415D-8260-E50A503A0C32Q35549083-DE1E416A-6D13-4A57-9552-A9637616308B
P2860
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@ast
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@en
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@nl
type
label
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@ast
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@en
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@nl
prefLabel
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@ast
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@en
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@nl
P2093
P2860
P50
P3181
P356
P1476
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
@en
P2093
Andrea Eisen
Barbara L Weber
Beth N Peshkin
Camille Corio
David M Euhus
Debra Dutson
Dianne Finkelstein
Donald A Berry
Edwin S Iversen
Gail Tomlinson
P2860
P304
P3181
P356
10.1200/JCO.2005.03.6772
P407
P577
2006-02-20T00:00:00Z